Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

RecBio (江苏瑞科) IPO: Fairly Valued on Optimistic Industry Forecast

RecBio (江苏瑞科) Pre-IPO:  Thoughts on Valuation

RecBio (江苏瑞科) Pre-IPO: A Pure Proxy to HPV Vaccine Market

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Jiangsu Recbio Technology / Equity Capital Markets

<ul>
<li>Jiangsu RecBio raised HKD 672m (USD 86m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday, March 31st.</li>
<li>In the previous note, we looked at the company's core products, including its HPV portfolio and the COVID-19 vaccine. </li>
<li>In this note, we provide an update for the IPO before trading debut.</li>
</ul>


Jiangsu RecBio raised HKD 672m (USD 86m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday, March 31st.
In the previous note, we looked at the company's core products, including its HPV portfolio and the COVID-19 vaccine. 
In this note, we provide an update for the IPO before trading debut.


RecBio (江苏瑞科) IPO Trading: Fairly Valued for Vaccine Hype